WO2003029284A1 - Anti-hiv agent - Google Patents
Anti-hiv agent Download PDFInfo
- Publication number
- WO2003029284A1 WO2003029284A1 PCT/JP2002/010119 JP0210119W WO03029284A1 WO 2003029284 A1 WO2003029284 A1 WO 2003029284A1 JP 0210119 W JP0210119 W JP 0210119W WO 03029284 A1 WO03029284 A1 WO 03029284A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- terminated
- modular
- modular structure
- composite
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
A polypeptide containing at least one of the following modular structures (1) to (3) and having the ability to bind to the N36 of human immunodeficiency virus; a composite thereof; and an anti-HIV agent or preventive or remedy for AIDS which contains the polypeptide or composite. (Y')m1-X1aX1b-A1-X1cX1dX1e-A2-(X')n1 : modular structure 1 (MS1) (Y')m2-X2a-A1A1-X2bX2c-A2A2-(X')n2 : modular structure 2 (MS2) (Y')m3-X3a-A1-X3bX3cX3d-A2-X' : modular structure 3 (MS3) {In the modular structures, A1 represents an acidic amino acid; A2 represents a basic amino acid; X1a to X3d are the same or different and each represents any desired amino acid; X' represents any desired amino acid which may have a protective group or represents -OR1 or -NR2R3; X' represents -OR4 or -NR5R6 (R1 to R6 are the same or different and each represents hydrogen, alkyl, aryl, or aralkyl); Y' represents hydrogen, R7CO- (R7 represents alkyl, optionally substituted phenyl, or optionally substituted benzyl), toluenesulfonyl, or methanesulfonyl; n1 and n2 each is 1 when MS1 and MS2 are terminated by carbon, and each is 0 when MS1 and MS2 are not terminated by carbon; m1 to m3 each is 1 when MS1, MS2, and MS3 are terminated by nitrogen, and each is 0 when MS1, MS2, and MS3 are not terminated by nitrogen; and in the modular structures (1) to (3) the amino acids each means -NH-CH(R')-CO- (R' represents a side chain of the amino acid).}
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-297963 | 2001-09-27 | ||
| JP2001297963 | 2001-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003029284A1 true WO2003029284A1 (en) | 2003-04-10 |
Family
ID=19118944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2002/010119 WO2003029284A1 (en) | 2001-09-27 | 2002-09-27 | Anti-hiv agent |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2003029284A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008013242A1 (en) * | 2006-07-27 | 2008-01-31 | Gekkeikan Sake Co., Ltd. | Method for production of n36-binding peptide |
| JP2020517741A (en) * | 2017-04-18 | 2020-06-18 | インスティテュート オブ パソジェン バイオロジー，チャイニーズ アカデミー オブ メディカル サイエンシズ | Lipopeptide, its derivative, its pharmaceutical composition and its use for potently inhibiting HIV |
| US11851422B2 (en) | 2021-07-09 | 2023-12-26 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12065428B2 (en) | 2021-09-17 | 2024-08-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006599A1 (en) * | 1998-07-30 | 2000-02-10 | Whitehead Institute For Biomedical Research | Inhibitors of hiv membrane fusion |
-
2002
- 2002-09-27 WO PCT/JP2002/010119 patent/WO2003029284A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006599A1 (en) * | 1998-07-30 | 2000-02-10 | Whitehead Institute For Biomedical Research | Inhibitors of hiv membrane fusion |
Non-Patent Citations (2)
| Title |
|---|
| MALASHKEVICH VLADIMIR N. ET AL.: "Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides", PROC. NATL. ACAD. ASCI. USA, vol. 95, no. 16, 4 August 1998 (1998-08-04), pages 9134 - 9139, XP002170630 * |
| SHIBO JIANG ET AL.: "A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 270, no. 1, 2000, pages 153 - 157, XP001121493 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008013242A1 (en) * | 2006-07-27 | 2008-01-31 | Gekkeikan Sake Co., Ltd. | Method for production of n36-binding peptide |
| JP2020517741A (en) * | 2017-04-18 | 2020-06-18 | インスティテュート オブ パソジェン バイオロジー，チャイニーズ アカデミー オブ メディカル サイエンシズ | Lipopeptide, its derivative, its pharmaceutical composition and its use for potently inhibiting HIV |
| JP7057822B2 (en) | 2017-04-18 | 2022-04-20 | インスティテュート オブ パソジェン バイオロジー，チャイニーズ アカデミー オブ メディカル サイエンシズ | Lipopeptides for strongly inhibiting HIV, derivatives thereof, pharmaceutical compositions thereof and their use |
| US11680086B2 (en) | 2017-04-18 | 2023-06-20 | Shanxi Kangbao Biological Product Co., Ltd. | Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereof |
| US11851422B2 (en) | 2021-07-09 | 2023-12-26 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12065428B2 (en) | 2021-09-17 | 2024-08-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69518910D1 (en) | METHOD FOR PRODUCING VIRAL VECTORS OF AT LEAST 20KB BY INTERMOLECULAR HOMOLOGOUS RECOMBINATION IN A PROKARYOTIC CELL | |
| RS100504A (en) | Hepatitis c virus inhibitors | |
| IL172015A (en) | Pyrimidine compounds having phosphonate groups, method for their preparation and their use in the manufacture of medicaments for treating viral infection | |
| FI901739A0 (en) | BENSIMIDAZOLER, DESSA FOERENINGAR INNEHAOLLANDE CEILING MODEL OCH FOERFARANDE FOER DERAS FRAMSTAELLNING. | |
| ATE503498T1 (en) | PEGYLATED GLYCOFORMS OF FACTOR VII | |
| DK0948527T3 (en) | Cylosporin derivatives, their preparation and pharmaceutical compositions containing them | |
| DE69311427D1 (en) | Synthetic polypeptides as inhibitors of HIV-1 | |
| ATE293171T1 (en) | RETROVIRAL HYBRID VECTORS PSEUDOTYPED WITH LCMV GLYCOPROTEIN | |
| MY111814A (en) | Watersoluble azole antifungals | |
| WO2003029284A1 (en) | Anti-hiv agent | |
| IL157540A0 (en) | N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof | |
| ES2163396T3 (en) | BIOLOGICALLY ACTIVE AMINAS. | |
| BR0312889A (en) | Pegged t20 polypeptide | |
| WO2004076474A3 (en) | Polyethylene glycol modified interferon compositions and methods of use thereof | |
| DE60132891D1 (en) | CYCLIC UREA COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | |
| EP0381340A3 (en) | Peptides with sulphate ester groups | |
| AU7383387A (en) | Amino acid derivatives | |
| AU1465301A (en) | Process for preparing n-(4-hydroxy-phenyl)-n'-(4'-aminophenyl)-piperazine | |
| DE502004002562D1 (en) | PROCESS FOR THE PRODUCTION OF HIGH-PURITY POLYALKYLENE GLYCOLS | |
| DE59404784D1 (en) | NEW CARBONIC ACID ESTERS OF 2-AMINO-7- (1,3-DIHYDROXY-2-PROPOXYMETHYL) PURIN, THEIR PRODUCTION AND USE THEREOF | |
| BR9913282A (en) | Substituted 3-aryl-pyrazoles | |
| ZA949973B (en) | Eburnane analogues a process for the preparation thereof and pharmaceutical compositions containing them | |
| NO305440B1 (en) | Gestagent active 19.11-wide 4- ° strands | |
| ATE441713T1 (en) | TUMOR ANTIGEN PROTEIN AND USE THEREOF | |
| PL348356A1 (en) | Substituted 1,3,5-triazines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS KE KG KR KZ LC LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |